⚠ GLAXF is no longer actively traded. Data shown reflects verified historical relationships.
Supply Chain Intelligence

GSK plc Supply Chain

GLAXF supply chain intelligence for GSK plc: verified suppliers, customers, debt relationships, acquisitions, and ownership data.

GLAXF ·Last updated 2026-07-30 · Interactive map →

Data compiled by Redley Lamar · ChainSifter Intelligence

5Suppliers
12Customers
1Debt Items
20Related Chains

GSK plc Suppliers

TickerNameConfidenceEvidence
KEY-SUPPLIERS KEY-SUPPLIERS 90% This improvement has been driven by successful engagement with suppliers.
SUSTAINABLE-MARKETS-INITIATIVE-SMI-HEALTH-SYSTEM SUSTAINABLE-MARKETS-INITIATIVE-SMI-HEALTH-SYSTEM 90% Through the Sustainable Markets Initiative (SMI) Health Systems Task Force, we co-led a Power Purchase Agreement (PPA) with peers and suppliers in China.
SMI-HEALTH-SYSTEMS-TASK-FORCE SMI-HEALTH-SYSTEMS-TASK-FORCE 85% Through the Sustainable Markets Initiative (SMI) Health Systems Task Force, we co-led a Power Purchase Agreement (PPA) with peers and suppliers in China.
12-COMPANIES 12-COMPANIES 80% This collaboration among 12 companies will unlock approximately 225 GWh of renewable electricity annually for the research, development and manufacture of medicines.
WWF WWF 80% To deliver water replenishment, we commenced a partnership with WWF.

GSK plc Customers

TickerNameConfidenceEvidence
GILD Gilead Sciences, Inc. 72% rporate and other unallocated impairment reversals ( 3 ) ( 14 ) – Other reconciling items between segment impairment reversals and total impairment reversals – – ( 1 ) Total impairment reversals ( 33…
GILD Gilead Sciences, Inc. 72% Reciprocal relationship from GILD graph: Reciprocal relationship from GLAXF graph: rporate and other unallocated impairment reversals ( 3 ) ( 14 ) – Other reconciling items between segment impairment…
HLNCF Haleon plc 72% Reciprocal relationship from HLNCF graph: Reciprocal relationship from GLAXF graph: r 2024 ( 110 ) ( 3,402 ) ( 3,512 ) Total accumulated amortisation and impairment at 31 December 2023 ( 1,382 ) ( 13…
HLNCF Haleon plc 72% r 2024 ( 110 ) ( 3,402 ) ( 3,512 ) Total accumulated amortisation and impairment at 31 December 2023 ( 1,382 ) ( 13,197 ) ( 14,579 ) Total accumulated amortisation and impairment at 31 December 2024 …
FLAGSHIP-PIONEERING-INC FLAGSHIP-PIONEERING-INC 62% r 2024 ( 110 ) ( 3,402 ) ( 3,512 ) Total accumulated amortisation and impairment at 31 December 2023 ( 1,382 ) ( 13,197 ) ( 14,579 ) Total accumulated amortisation and impairment at 31 December 2024 …
LEASES-THE-GROUP LEASES-THE-GROUP 62% is recognised when it is highly probable that the sales threshold will be reached. Sales-based royalties on a licence of intellectual property are not recognised until the relevant product sale occur…
REGISTERED-AGENT-PINK-ONION-LLC REGISTERED-AGENT-PINK-ONION-LLC 62% hair of Genetics and Professor of Genetics (& Pathology), Harvard Medical School; Chair of Molecular Biology, Massachusetts General Hospital; Co-Founder and Consultant, Fulcrum Therapeutics; Scientif…
SEE-GROUP SEE-GROUP 62% . Our long-acting medicines continue to see increased momentum and are critical to our long-term growth. By the end of 2024 they represented 20% of total HIV sales compared to 16% for 2023 and contri…
SIERRA-ONCOLOGY-INC SIERRA-ONCOLOGY-INC 62% n has been recognised. The goodwill represents specific synergies available to GSK from the business combination. The goodwill has been allocated to the Group’s R&D segment. None of the goodwill is e…
SKYHAWK-THERAPEUTICS-INC SKYHAWK-THERAPEUTICS-INC 62% hair of Genetics and Professor of Genetics (& Pathology), Harvard Medical School; Chair of Molecular Biology, Massachusetts General Hospital; Co-Founder and Consultant, Fulcrum Therapeutics; Scientif…
TURNOVER-REPORTED-GROUP TURNOVER-REPORTED-GROUP 62% st contracts which have been separated from the host contract, are measured at fair value. Changes in the fair value of any derivative instruments that do not qualify for hedge accounting are recogni…
ZANTAC-THE-GROUP ZANTAC-THE-GROUP 62% laintiffs’ motion for class certification for 12 March 2025, and a hearing on GSK’s motion for summary judgment for 21 April 2025. Zantac The Group has been named in product liability lawsuits on beh…

GSK plc Debt Obligations

InstrumentDescriptionConfidenceEvidence
GLAXF-DEBT Debt stack $25.5B 90% Market cache reports total debt of $25.5B.

GSK plc Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for GSK plc.

GSK plc Ownership

HolderNameConfidenceEvidence
GLAXF-OWNER-DZ-BANK-AG-DEUTSCHE-ZENTRAL-GENO DZ BANK AG Deutsche Zentral Genossenschafts Bank, Frankfurt am Main 90% 13F overlay lists DZ BANK AG Deutsche Zentral Genossenschafts Bank, Frankfurt am Main as top holder; 5 tracked holders.

GSK plc Extended Supply Chain Network

TickerNameChain IndexHopsRelationship Types
DTEGY Deutsche Telekom AG 100.00 2
CRIS Curis, Inc. 100.00 2
SFGYY Sony Financial Group Inc. 100.00 2
CAH Cardinal Health, Inc. 100.00 2
ADI Analog Devices, Inc. 100.00 2
CAJPY Canon Inc. 100.00 2
CTNM Contineum Therapeutics, Inc. 100.00 2
BCAX Bicara Therapeutics Inc. 100.00 2
DYN Dyne Therapeutics, Inc. 100.00 2
DEO Diageo plc 100.00 2
AVIR Atea Pharmaceuticals, Inc. 100.00 2
UNLYF Unilever PLC 100.00 2
CLX The Clorox Company 100.00 2
ACET Adicet Bio, Inc. 100.00 2
TDC Teradata Corporation 100.00 2
SDGR Schrödinger, Inc. 100.00 2
CHRS Coherus Oncology, Inc. 100.00 2
BDRX Biodexa Pharmaceuticals Plc 100.00 2
CABA Cabaletta Bio, Inc. 100.00 2
VEEV Veeva Systems Inc. 100.00 2
View GLAXF supply chain intel →

Explore the full interactive supply chain map for GSK plc.

Open GLAXF supply chain map →
ChainSifter · Guerilla Finance Terms Disclaimer ← Back to Map